	US 12,186,389 B2
	Nucleic acid base vaccine against emerging SARS-CoV-2 variants
Benjamin Petsch, Tübingen (DE); Dominik Vahrenhorst, Tübingen (DE); Diego Chaves Moreno, Tübingen (DE); Janina Gergen, Tübingen (DE); Jessica Michelle Devant, Tübingen (DE); Kristina Kovacikova, Tübingen (DE); and Hans Wolfgang Große, Tübingen (DE)
Assigned to GlaxoSmithKline Biologicals SA, (BE)
Filed by GlaxoSmithKline Biologicals SA, Rixensart (BE)
Filed on Oct. 26, 2023, as Appl. No. 18/494,893.
Claims priority of application No. 2216023 (GB), filed on Oct. 28, 2022; application No. 2300950 (GB), filed on Jan. 23, 2023; application No. 2308048 (GB), filed on May 30, 2023; and application No. 2311985 (GB), filed on Aug. 4, 2023.
Prior Publication US 2024/0156949 A1, May 16, 2024
Int. Cl. A61K 39/215 (2006.01); A61P 31/14 (2006.01); C07K 14/005 (2006.01); C07K 14/165 (2006.01); A61K 39/00 (2006.01)

CPC A61K 39/215 (2013.01) [A61P 31/14 (2018.01); C07K 14/005 (2013.01); A61K 2039/53 (2013.01); A61K 2039/545 (2013.01); A61K 2039/55555 (2013.01); C07K 14/165 (2013.01); C12N 2770/20022 (2013.01); C12N 2770/20034 (2013.01)]

28 Claims

1. An mRNA comprising at least one coding sequence encoding at least one SARS-COV-2 spike protein, wherein said SARS-COV-2 spike protein is at least 95% identical to the amino acid sequence of SEQ ID NO: 162 and comprises the following amino acid substitutions or deletions relative to SEQ ID NO: 1: K986P, V987P, T19I, L24del, P25del, P26del, A27S, V83A, G142D, Y144del, H146Q, Q183E, V213E, G252V, G339H, R346T, L368I, S371F, S373P, S375F, T376A, D405N, R408S, K417N, N440K, V445P, G446S, N460K, S477N, T478K, E484A, F486P, F490S, Q498R, N501Y, Y505H, D614G, H655Y, N679K, P681H, N764K, D796Y, Q954H and N969K.